Dosage regimen for a pi-3 kinase inhibitor

摘要

Disclosed is the use of a compound 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-ylamine or a pharmaceutically acceptable salt thereof in the preparation of a medicament for use in the treatment of a proliferative disease wherein the medicament comprising about 60 to about 120 mg of compound 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-ylamine or a pharmaceutically acceptable salt thereof is adapted for administered to a human patient in need thereof for five consecutive days in any seven day period.